The National Lipid Association (NLA) welcomes the results of the REVEAL trial which demonstrated that reductions in cholesterol levels with anacetrapib were associated with a reduction in cardiovascular events. Specifically, cholesterol drug anacetrapib produced reductions in low density lipoprotein (LDL) cholesterol levels, non-high density lipoprotein (non-HDL) cholesterol levels, lipoprotein(a) levels and a profound increase in high density lipoprotein (HDL) cholesterol levels. These favorable lipid changes were associated with a significant reduction in cardiovascular events
The American Board of Clinical Lipidology (ABCL) Board of Directors has published a list of recommended reading for those preparing for maintenance of certification (MOC). If you’re studying for the exam, you can find a list of suggested reading at lipidboard.org/moc.
JACKSONVILLE, Fla. – The Foundation of the NLA launched its RADAR (RAre Disease AwarReness) campaign and redesigned website, learnyourlipids.com on Monday.